Modernavs.Regeneron
MRNA vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 1.2× larger than Regeneron by market cap; year to date, Moderna leads (+568.0% vs −4.2%).
Side by side
| MRNA | REGN | |
|---|---|---|
| Market cap | $88.6B | $76.1B |
| Price | $225.00 | $746.54 |
| Today | +14.2% | +0.9% |
| Return YTD | +568.0% | −4.2% |
| Return 1Y | +605.6% | +31.2% |
| Since June 26, 2026 | +234.5% | +18.0% |
| P/E | — | 17.6 |
| P/S | 39.8 | 4.9 |
| P/B | 13.1 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More MRNA & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.